The latest evolution in nonsurgical body contouring began last year with muscle-toning technology Emsculpt (BTL). Two other similar devices entered the market soon after to claim some of that noninvasive market share: Cooltone by Coolsculpting (Allergan) and truSculpt flex (Cutera).
The muscle stimulating devices noninvasively tone and stimulate muscle just enough to give reasonably fit patients a more sculpted look and feel.
Unlike volume reduction devices, such as Coolsculpting (Allergan), TruSculpt iD (Cutera) or SculpSure (Cynosure), muscle stimulating technology works to tone and shape by hyper stimulating the underlying muscle. The ideal candidate — one that is fit with minimal body fat — will likely by most satisfied from the investment, according to experts.
But results are temporary and treatments expensive, often in the range of $750 to $1,000 per treatment area. And having one of these devices is a sizeable investment for an aesthetic practice.
So, how does an aesthetic practice decide whether to invest in one of these technologies? We asked several aesthetic physicians to share what they’ve learned about what differentiates the technologies and more.
A QUESTION OF ROI
Plastic surgeon Christie Prendergast, M.D., Santa Monica, Calif., says Emsculpt has the advantage of being the first muscle-building and sculpting device on the market. That means it has more brand recognition to consumers than the others. However, adding Emsculpt to a practice comes at a hefty price.
Dr. Belkin practices at the Laser & Skin Surgery Center of New York, which was one of the research facilities that tested Cooltone.